Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition

Acta Neurologica Scandinavica

Volumn 115, Issue 4, 2007, Pages 232-242

  Simon, C ^a   Stieger, B ^b   Kullak Ublick, G A ^b   Fried, M ^b   Mueller, S ^a   Fritschy, J M ^c   Wieser, H G ^a   Pauli Magnus, C ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antiepileptic drugs; Carbamazepine; Cytochrome P450; Epilepsy; Intestinal absorption; MDR1; MRP2; Phenytoin

Indexed keywords

ABC TRANSPORTER; ACETAZOLAMIDE; ALENDRONIC ACID; ATENOLOL; CARBAMAZEPINE; CELECOXIB; CLOBAZAM; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIAZEPAM; DNA; ETIRACETAM; FELODIPINE; GABAPENTIN; LAMOTRIGINE; LEVOTHYROXINE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NADOLOL; OXCARBAZEPINE; PERINDOPRIL; PHENOBARBITAL; PHENYTOIN; PRAVASTATIN; TEMOZOLOMIDE; THALIDOMIDE; TIBOLONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MEGADOSE; DRUG TRANSPORT; DUODENUM BIOPSY; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTESTINE ABSORPTION; LOW DRUG DOSE; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; ANTICONVULSANTS; ATP-BINDING CASSETTE TRANSPORTERS; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; POLYMORPHISM, GENETIC;

EID: 33947429086     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00761.x     Document Type: Article

References (44)

1. BAJPAI M, ROSKOS LK, SHEN DD, LEVY RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3.
2. DOECKE CJ, VERONESE ME, POND SM et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991;31:125-30.
3. KERR BM, THUMMEL KE, WURDEN CJ et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
4. VERONESE ME, MACKENZIE PI, DOECKE CJ, MCMANUS ME, MINERS JO, BIRKETT DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
5. POTSCHKA H, FEDROWITZ M, LOSCHER W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR-rats. Epilepsia 2003;44:1479-86.
6. POTSCHKA H, FEDROWITZ M, LOSCHER W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003;306:124- 31.
7. POTSCHKA H, LOSCHER W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42:1231-40.
8. SCHINKEL AH, WAGENAAR E, MOL CA, VAN DEEMTER L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
9. WANG-TILZ Y, TILZ C, WANG B, TILZ GP, STEFAN H. Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. Epilepsia 2006;47:233-9.
10. POTSCHKA H, FEDROWITZ M, LOSCHER W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001; 12:3557-60.
11. SEO T, ISHITSU T, UEDA N et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006;7:551-61.
12. SIDDIQUI A, KERB R, WEALE ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8.
13. OWEN A, PIRMOHAMED M, TETTEY JN, MORGAN P, CHADWICK D, PARK BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51:345-9.
14. DURR D, STIEGER B, KULLAK-UBLICK GA et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
15. PINTO AG, WANG YH, CHALASANI N et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005;77:178-88.
16. MORIN S, LORIOT MA, POIRIER JM et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 2001;56:793-7.
17. FROMM MF, KIM RB, STEIN CM, WILKINSON GR, RODEN DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-7.
18. GREINER B, EICHELBAUM M, FRITZ P et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
19. FROMM MF, KAUMANN HM, FRITZ P et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000;157:1575-80.
20. KERB R, AYNACIOGLU AS, BROCKMOLLER J et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-10.
21. MAMIYA K, IEIRI I, MIYAHARA S et al. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics 1998;8:87-90.
22. ODANI A, HASHIMOTO Y, OTSUKI Y et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997;62:287-92.
23. KROETZ D, PAULI-MAGNUS C, HODGES L et al. Sequence diversity and haplotype structure in the human MDR1 gene. Pharmacogenetics 2003;13:461-73.
24. ZIMPRICH F, SUNDER-PLASSMANN R, STOGMANN E et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004;63:1087-9.
25. MEIER Y, PAULI-MAGNUS C, ZANGER UM et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006;44:62-74.
26. ENGEL J JR. Update on surgical treatment of the epilepsies. Summary of the Second International Palm Desert Conference on the Surgical Treatment of the Epilepsies (1992). Neurology 1993;43:1612-7.
27. WIESER HG, BLUME WT, FISH D et al. ILAE Commission Report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia 2001;42:282-6.
28. LIU H, DELGADO MR. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children. Epilepsia 1995;36:249-54.
29. BROWNE TR, SZABO GK, EVANS J, EVANS BA, GREENBLATT DJ, MIKATI MA. Phenobarbital does not alter phenytoin steady-state serum concentration or pharmacokinetics. Neurology 1988;38:639-42.
30. SMITH PK, KROHN RI, HERMANSON GT et al. Measurement of protein using bicinchoninic acid. Analytical biochemistry 1985;150:76-85.
31. TANABE M, IEIRI I, NAGATA N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
32. SANGER F, AIR GM, BARRELL BG et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature 1977;265:687-95.
33. GOLDSTEIN JA, DE MORAIS SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
34. MIZUTANI T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003;35:99-106.
35. STAINES AG, COUGHTRIE MW, BURCHELL B. N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther 2004;311:1131-7.
36. STRASSBURG CP, KNEIP S, TOPP J et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 2000;275:36164-71.
37. GIESSMANN T, MAY K, MODESS C et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004;76:192-200.
38. MAHER JM, CHENG X, SLITT AL, DIETER MZ, KLAASSEN CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005;33:956-62.
39. LUO G, CUNNINGHAM M, KIM S et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804.
40. MICELI JJ, ANZIANO RJ, ROBARGE L, HANSEN RA, LAURENT A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000;49(Suppl. 1):65S-70S.
41. LAPPLE F, VON RICHTER O, FROMM MF et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003;13:565-75.
42. HOMEYER S, BURK O, VON RICHTER O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
43. MACPHEE IA, FREDERICKS S, TAI T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486-9.
44. YASARGIL MG, WIESER HG, VALAVANIS A, VON AMMON K, ROTH P. Surgery and results of selective amygdala-hippocampectomy in one hundred patients with nonlesional limbic epilepsy. Neurosurg Clin N Am 1993;4:243-61.